Arthur T. Sands - 10 Feb 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
President, CEO, Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Arthur T. Sands
Issuer symbol
NRIX
Transactions as of
10 Feb 2026
Net transactions value
$0
Form type
4
Filing time
10 Feb 2026, 17:43:09 UTC
Previous filing
13 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SANDS ARTHUR T President, CEO, Director C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE /s/ Daniel Burbach, as Attorney-in-Fact for Arthur T. Sands 10 Feb 2026 0001134106

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +562,500 $0.000000 562,500 10 Feb 2026 Common Stock 562,500 $16.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.